Navigation Links
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Date:2/26/2008

drug. Nexavar is currently approved for the treatment of advanced kidney cancer and liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding Dr. Coles' anticipated contributions to Onyx, the progress and results of the clinical development, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NPS Pharmaceuticals Announces Senior Management Changes
2. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
3. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
7. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
8. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
9. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... firm, Ernst & Young LLP ("EY") that it was resigning ... letter delivered to the Company on September 15, 2014 and ... PDL has issued the following statement in ... number of inquiries on the reason for the resignation of ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2
... to complement VAP advanced cholesterol profileORLANDO, Fla. and ... of the VAP Cholesterol Test, has announced the ... at ACC.09, the American College of Cardiology (ACC) ... more than a dozen new tests, including C-Reactive ...
... January, the industry seems to have taken a deep breath and a step ... cuts that were announced were mostly due to the overall economic difficulty facing ... ... to say the worst is past for health care, it does seem as ...
... Phase 3 programCRANBURY, N.J., March 28 Amicus Therapeutics ... from its ongoing Phase 2 extension study of its ... The results will be presented at the American College ... FL. Phase 2 Extension Study Overview: Twenty-six ...
Cached Biology Technology:Atherotech Unveils New Cardiometabolic Test Panels 2Atherotech Unveils New Cardiometabolic Test Panels 3The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 2Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 4Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 5
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Di Benedetto and Micaela Caramellino, two doctoral ... received recognition at a student poster event organized ... nano- and micro-sized drug particles. The New Jersey ... was the sponsor. In recent years, ...
... Technology Business Assessment Group will fund four faculty ... identified these one-year projects from a number of ... earlier this spring. Funding for the program ... Property Management, and is generated by royalties from ...
... released today in the online edition of Physiological Genomics finds ... sugary foods. The study offers the first evidence of the ... gene that controls sugar entry into the cells has ... foods high in sugar. The study was conducted ...
Cached Biology News:NJIT doctoral students receive recognition at poster competition 2OSU technologies funded for development 2OSU technologies funded for development 3Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3
Request Info...
Request Info...
Request Info...
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
Biology Products: